LitCovid-sentences  

PubMed:33152450 JSONTXT 19 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 0-126 Sentence denotes Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial.
T2 127-138 Sentence denotes BACKGROUND:
T3 139-226 Sentence denotes There are no effective therapies for patients with Coronavirus disease-2019 (COVID-19).
T4 227-235 Sentence denotes METHODS:
T5 236-402 Sentence denotes Forty-one patients with confirmed COVID-19 were enrolled in the study and divided into two groups: artemisinin-piperaquine (AP) group (n=23) and control group (n=18).
T6 403-624 Sentence denotes The primary outcome was the time taken to reach undetectable levels of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and the percentage of participants with undetectable SARS-CoV-2 on day 7, 10, 14, and 28.
T7 625-801 Sentence denotes The computed tomography (CT) imaging changes within ten days, the corrected QT interval changes, adverse events, and abnormal laboratory parameters were the secondary outcomes.
T8 802-810 Sentence denotes RESULTS:
T9 811-932 Sentence denotes The mean time to reach undetectable viral RNA (mean± standard deviation) was 10.6±1.1 days (95% confidence interval [CI]:
T10 933-982 Sentence denotes 8.4-12.8) for AP group and 19.3±2.1 days (95% CI:
T11 983-1016 Sentence denotes 15.1-23.5) for the control group.
T12 1017-1249 Sentence denotes The percentage of patients with undetectable viral RNA on day 7, 10, 14, 21, and 28 were 26.1%, 43.5%, 78.3%, 100%, and 100%, respectively, in the AP group and 5.6%, 16.7%, 44.4%, 55.6% and 72.2%, respectively, in the control group.
T13 1250-1362 Sentence denotes The CT imaging within ten days post-treatment showed no significant differences between the two groups (p>0.05).
T14 1363-1399 Sentence denotes Both groups had mild adverse events.
T15 1400-1412 Sentence denotes CONCLUSIONS:
T16 1413-1572 Sentence denotes In patients with mild to moderate COVID-19, the time to reach undetectable SARS-CoV-2 was significantly shorter in the AP group than that in the control group.
T17 1573-1649 Sentence denotes However, physicians should consider the QT interval changes before using AP.